SAREPTA THERAPEUTICS INC (SRPT) Stock News
NASDAQ:SRPT - Nasdaq - US8036071004 - Common Stock - Currency: USD
SRPT Latest News, Press Relases and Analysis
Jim Cramer Notes Eli Lilly (LLY) Stock is at a “Decent Level to Start a Position”
We recently published a list of Jim Cramer Had These 21 Stocks on His Radar. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses. A caller asked what Cramer’s thoughts on Eli Lilly and Company (NYSE:LLY) were, and he […]
Was Jim Cramer Right About AST SpaceMobile, Inc. (ASTS)?
We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where AST SpaceMobile, Inc. (NASDAQ:ASTS) stands against other stocks that Jim Cramer discusses. A caller asked about AST SpaceMobile, Inc. (NASDAQ:ASTS), wondering about its potential despite having no earnings yet. […]
Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?
We recently published a list of Was Jim Cramer Right About These 11 Stocks? In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) stands against other stocks that Jim Cramer discusses. A caller asked about Sarepta Therapeutics Inc. (NASDAQ:SRPT), a biotech firm working on RNA therapies. Cramer responded […]
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next
Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying
Mentions: TLRY
Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential
We recently published a list of Billionaire Glenn Russell Dubin’s 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against Billionaire Glenn Russell Dubin’s other stock picks with huge upside potential. Glenn Russell Dubin is one of the industry’s most […]
Mentions: JPM
Sarepta’s Week Goes From Bad to Worse on FDA Fears, Outlook Cut
Sarepta Therapeutics Inc. is on pace for its worst week in four years as disappointing earnings and regulatory fears hit the drugmaker’s shares.
Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
Sarepta price target lowered to $125 from $183 at Needham
Needham lowered the firm’s price target on Sarepta (SRPT) to $125 from $183 and keeps a Buy rating on the shares. The company faced significant pressure following earnings, triggered by the appointment of Vinay Prasad to head CBER, as Dr. Prasad is a known critic of the accelerated approval pathway and Elevidys’ approval in particular, the analyst tells investors in a research note. Sarepta has also lowered FY25 sales guidance, Needham notes, adding however that it still views the stock as “unde
Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
We recently published an article titled Why These 10 Firms Nosedived Today. In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. The stock market bounced back from the previous day’s losses, with all major indices finishing higher as investors cheered the central bank’s decision to […]
The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.